GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Blue Jet Healthcare BLUEJET.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

543.55

-1.85%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Blue Jet Healthcare

Its shares trade on NSE under the ticker BLUEJET.NS. It has been listed since 1 November 2023. In the fiscal year to 31 March 2026, it reported revenue of ₹9.47bn and net income of ₹2.48bn. At that date it held total assets of ₹16.41bn and shareholders' equity of ₹13.60bn.

Blue Jet Healthcare Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2023-11-01. Blue Jet Healthcare Limited is an India-based specialty pharmaceutical and healthcare ingredients and intermediates company. The Company’s operations are primarily organized in three product categories: contrast media intermediates, high-intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs). Contrast media are agents used in medical imaging to enhance the visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound. Its high-intensity sweetener business includes development, manufacturing and marketing of saccharin and its salts. The Company’s contract development and manufacturing organization (CDMO) activity in the pharma intermediate and API business is primarily focused on collaborating with innovator pharmaceutical companies and multi-national generic pharmaceutical companies by providing them with pharma intermediates that serve as building blocks for APIs in chronic therapeutic areas.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
1 Nov 2023

Leadership

Pay as last reported

  • Mr. Akshay AroraExecutive Chairman of the Board₹36.0m
  • Mr. Ganesh KaruppannanChief Financial Officer₹21.7m
  • Mr. Vimalendu SinghChief Operating Officer₹27.8m
  • Ms. Sweta PoddarCompliance Officer, Company Secretary₹1.7m
  • Mr. Shiven AroraManaging Director, Executive Director₹51.7m
  • Mr. Popat KedarExecutive Whole-Time Director, since 2020
  • Mr. Naresh ShahExecutive Director, since 2020₹30.0m
  • Ms. Preeti MehtaNon-Executive Independent Director₹1.9m
  • Ms. Divya MomayaNon-Executive Independent Director₹800,000
  • Mr. Girish VanvariNon-Executive Independent Director₹1.9m
  • Ms. Priyanka YadavNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Blue Jet Healthcare specializes in contrast media intermediates for medical imaging in India.
  • The company develops and markets saccharin-based high-intensity sweeteners for the food industry.
  • Blue Jet Healthcare offers CDMO services for pharma intermediates and APIs to global pharmaceutical firms.

Weaknesses

  • Blue Jet Healthcare's IPO was only recently listed on 1 November 2023.
  • The company's operations are limited to three product categories in the pharmaceutical sector.
  • Blue Jet Healthcare has no presence in international markets beyond India.

Opportunities

  • The growing demand for medical imaging contrast media in India presents expansion opportunities.
  • India's pharmaceutical sector is expanding rapidly with increasing global demand.
  • The high-intensity sweetener market in India is growing due to health-conscious consumer trends.

Threats

  • Competition from established pharmaceutical companies in India poses a threat to market share.
  • Regulatory changes in the Indian pharmaceutical industry could impact operations.
  • The reliance on a single country market increases vulnerability to local economic fluctuations.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.